维普期刊资源整合服务平台（V6.5）

35篇 您的检索式：作者名="GROSSER T"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Biological basis for the cardiovascular consequences of COX-2 inhibition:therapeutic challenges and opportunities显示文摘	Grosser T Fries S FitzGerald GA	2006	J Clin Invest2006，116，1：	1
2	Exogenous estrogen does not at enuate the association between rofecoxib and myocardial infarction in perimenopausal women显示文摘	Wade KC Ellenberg JH Grosser T		0，，：	1
3	Length - dependent DNA separations using multiple end - attached peptide nucleic acid amphiphiles in micellar electrokinetic chromatography显示文摘	Savard J M Grosser S T Schneider J W	2008	Electrophoresis2008，29，：	1
4	Drug resist- ance and pseudoresistanee: an unintended conse- quence of enteric coating aspirin 显示文摘	Grosser T Fries S Lawson JA	2013	Circulation2013，127，3：	1
5	The translational therapeutics of prostaglandin inhibition in atherothrom- bosis显示文摘	Yu Y Ricciotti E Grosser T	2009	J Thromb Haemost2009，7，1：	1
6	Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities 显示文摘	GROSSER T FRIES S FITZGERALD G A	2006	J Clin Invest2006，116，：	1
7	Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities 显示文摘	Grosser T FriesS FitzGerald GA	2006	J Clin Invest2006，116，：	1
8	Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities 显示文摘	Grosser T Fries S Fitz GA	2006	Clin Invest2006，116，1：	1
9	J Biological basis for The cardiovascular conseguences of COX-2 inhibition:Therapeutic challenges and opportunities 显示文摘	Grosser T Fries S Fitzgerald GA	2006	Clin Invest2006，116，1：	1
10	Biological basis for the cardiovascular consequences of COX-2 inhibition:therapeutic challenges and opportunities显示文摘	Grosser T Fries S Fitz Gerald G A	2006	J Clin Invest2006，116，1：	1
11	Biological basis for the car-diovascular consequences of COX-2inhibition:therapeutic chal-lenges and opportunities显示文摘	Grosser T Fries S Fitzgerald G A	2006	J Clin Invest2006，116，1：	1
12	Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin 显示文摘	GROSSER T FRIES S LAWSON J A	2013	Circulation2013，127，3：	1
13	Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities显示文摘	Grosser T Fries S Fitzgerald G A	2006	J Clin Invest2006，116，1：	1
14	Emotion recollected in tranquility: lessons learned from the COX-2 saga 显示文摘	Grosser T Yu Y Fitzgerald GA	2010	Annu Rev Med2010，61，9：	1
15	Drug resistance and pseud-oresistance:an unintended consequence of enteric coating aspirin 显示文摘	Grosser T Fries S Lawson JA	2013	Circulation2013，，127：	1
16	Prostanoids in health and dis- ease显示文摘	Smyth EM Grosser T Wang M	2009	J Lipid Res2009，，：	1
17	Marked interindividual variability in the response to selective inhibitors of cyclooxygenase - 2 显示文摘	Fries S Grosser T Price T S	2006	Gastroenterology2006，130，1：	1
18	Developmental expressionof functional cyclooxygenases in zebrafish 显示文摘	Grosser T Yusuff S Cheskis E	2002	Proc NatlAcad Sci USA2002，99，12：	1
19	J Biological basis for the cardiovascular consequences of COX-2 inhibition:therapeutic challenges and opportunities显示文摘	Grosser T Fries S FitzGerald GA	2006	Clin Invest2006，116，1：	1
20	Prostanoids and inflammatory pain 显示文摘	Chen L H Yang G R Grosser T	2012	Prostaglandins Other Lipid Mediat2012，104，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示